Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 24, 2025
Following Qiming Venture Partners' portfolio companies and their milestone moments with you
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth recording. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in marking the milestone moments of our portfolio companies.
Corporate ESG
WeRide Supports Inclusive Care Program for Children and Adolescents with Intellectual Disabilities
Recently, the "CapitaLand · Xinrong Project — Make a 'Star' Friend: Co-Creation and Inclusive Care Program for Children and Adolescents with Intellectual Disabilities, 'Star' Journey — Guangzhou Somerset Bio-Island Service Apartment Special Event," jointly initiated by Ascott properties and hotels in the Guangzhou region, organized by the Guangzhou Yang'ai Special Children Parents Club, and supported by Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD), opened on Guangzhou Bio-Island.
During the event, WeRide prepared a "Star Wish Fleet" composed of autonomous shuttle buses (Robobuses) for the "heart youths," allowing them to experience cutting-edge technology while feeling that "unmanned" can be another form of companionship. Additionally, WeRide held an interactive and prize-winning mini-class on "What is Autonomous Driving," combining education with entertainment to help the "heart youths" deepen their understanding of autonomous driving technology in a relaxed and enjoyable atmosphere.
Funding News
Zhipu AI Receives Strategic Investment and Announces Two Latest Achievements
Recently, Qiming Venture Partners portfolio company Zhipu AI announced at its Open Platform Industry Ecosystem Conference that it has received a strategic investment, which will inject solid momentum into building trustworthy AI infrastructure.
Zhipu AI CEO Zhang Peng announced two latest achievements in the company's march toward AGI with ecosystem partners during his keynote speech: first, the open-source release of the next-generation general vision-language model GLM-4.1V-Thinking, which breaks through with reasoning capabilities and sets new performance benchmarks for 10B-level multimodal models; and second, the launch of the "App Space" Agent aggregation platform on MaaS, fully activating AI capabilities across industry scenarios, alongside the Z Fund's launch of the Agent Pioneer special support program.
Major Partnerships
01/
HyperStrong Reaches Strategic Partnership with European Large-Scale Energy Storage Developer Repono
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) formally reached a strategic partnership with European large-scale energy storage project developer Repono. The two parties will jointly advance grid-scale energy storage projects totaling 1.4 GWh by 2027, further accelerating Europe's energy transition and helping build a resilient, sustainable green energy system.
This strategic partnership is a model of China-Europe energy storage industry cooperation. Repono will fully leverage its extensive experience in project development, site selection, grid connection, and permitting, while HyperStrong will provide integrated solutions covering energy storage system delivery, system integration, and full-lifecycle services. The two parties' strong alliance and complementary advantages will drive rapid deployment and high-quality implementation of grid-scale energy storage projects.
02/
HyperStrong Signs Framework Cooperation Agreement with Singapore Energy Infrastructure Developer Alpina
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) signed a framework cooperation memorandum of understanding with Singapore energy infrastructure developer Alpina. HyperStrong will provide 5,000 integrated charging and storage units to the company from 2025 to 2027, working together to develop the Singapore and Asia-Pacific markets, realizing energy storage applications in the rapidly growing electric vehicle charging market, and jointly injecting strong momentum into the integrated development of energy storage and charging in the Asia-Pacific region.
In this cooperation, HyperStrong's product offering is full of highlights. As a newly upgraded fully liquid-cooled integrated charging and storage unit, the product features built-in semi-solid-state batteries and AI-powered intelligent early warning capabilities, with comprehensive three-dimensional fire protection achieving detection, prevention, venting, and suppression for multiple layers of protection and intrinsic safety at charging stations. The entire station shares energy, supporting DC and AC coupling, integrating multiple energy conversions including solar and wind power to achieve full-station green electricity. With equivalent transformer capacity, charging piles can be over-provisioned by 2-5x, using energy storage to provide power support, increasing station charging capacity by 40%-80% and deferring transformer upgrade needs. The product also supports six application scenarios — peak shaving and valley filling, demand control, station capacity expansion, virtual power plants, reactive power regulation, and backup power — enabling diversified revenue streams.
03/
Shangyue and Bear Electric Launch Non-Production Procurement System Project
Recently, the kickoff meeting for the non-production procurement system project of Bear Electric Co., Ltd. ("Bear Electric"), built by Qiming Venture Partners portfolio company Shangyue, was successfully held.
The system will achieve full-chain digitalization and online processing from procurement planning to reconciliation and settlement, unifying the centralized procurement portal, standardizing procurement processes, and consolidating fragmented demand to build a new "sunshine procurement" ecosystem. The system will deeply integrate with Bear Electric's existing ERP, OA, financial, and IDM systems to achieve full-process online collaboration and closed-loop control; introduce self-service procurement and RPA technology to reduce transactional work and significantly improve human efficiency; and configure intelligent workstations by role to optimize internal and external collaboration experiences. Through Shangyue's highly reliable technical architecture, data security and governance capabilities will be strengthened to ensure stable system operation; at the same time, the platform features high flexibility and scalability, fully supporting Bear Electric's future procurement digitalization business expansion needs.
04/
Wanzhongyixin Becomes Member of "Chengdu Regional Clinical Research Alliance"
Recently, the "Chengdu Regional Clinical Research Alliance" was formally inaugurated. As an innovative biomedical enterprise, Qiming Venture Partners portfolio company Wanzhongyixin was invited to attend the launch event and officially became a member of the alliance.
The alliance aims to build a clinical research quality management system, break down resource barriers, unify standards, and connect translation pathways to create a fast track for multi-center clinical trial collaboration and innovation, integrate clinical research resources within Chengdu's jurisdiction, promote dual upgrades in "research and service," effectively enhance drug and medical device clinical trial research capabilities in the Chengdu region, help enterprises achieve precise resource matching, drive the dual engines of R&D "cost reduction and speed increase," accelerate the promotion of new drug development and advanced therapies, and inject new momentum into building a competitive biomedical innovation ecosystem in Chengdu.
Wanzhongyixin will work hand in hand with all member units of the Chengdu Regional Clinical Research Alliance, carrying out comprehensive cooperation in clinical research, technological innovation, and成果转化, jointly exploring clinical research models and innovation paths suited to regional characteristics.
R&D Progress
01/
Insilico Medicine Publishes AI-Driven Innovative Design Strategy for Highly Selective FGFR2/3 Inhibitors
Qiming Venture Partners portfolio company Insilico Medicine recently published a study in the Journal of Medicinal Chemistry, combining advanced molecular modeling techniques with the company's self-developed generative AI-based chemistry engine Chemistry42 to efficiently develop highly selective FGFR2/3 inhibitors featuring novel core scaffolds — offering innovative approaches for next-generation targeted cancer therapies against FGFR2/3.
"This study not only demonstrates the high efficiency and precision of AI-enabled drug design, but also highlights the importance of rigorous experimental validation," said Dr. Xiao Ding, Senior Vice President of Insilico Medicine and Head of Chemistry and DMPK. "Building on these findings, the industry can expect further breakthroughs in moving from computer simulation toward clinically meaningful therapeutic options in the real world."
02/
Zai Lab Partner Announces TTFields Therapy
Phase 3 PANOVA-3 Clinical Study Results in Pancreatic Cancer
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) partner Novocure presented the final secondary endpoint results from the phase 3 PANOVA-3 clinical study of Tumor Treating Fields (TTFields) therapy in unresectable locally advanced pancreatic cancer as an oral presentation at the 2025 ESMO Gastrointestinal Cancers Congress. Data from the PANOVA-3 study were accepted as a late-breaking abstract at the congress.
The PANOVA-3 study evaluated the efficacy of TTFields therapy combined with gemcitabine and nab-paclitaxel (GnP) versus GnP alone as first-line treatment for unresectable locally advanced pancreatic cancer. The study met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients receiving TTFields therapy.
03/
Zai Lab Announces Positive Results from Prespecified Interim Analysis of Phase 3 Study of Bemarituzumab as First-Line Treatment
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced that the phase 3 FORTITUDE-101 clinical study evaluating bemarituzumab combined with chemotherapy (mFOLFOX6) as first-line treatment met its primary endpoint of overall survival (OS) at a prespecified interim analysis.
In patients with FGFR2b-overexpressing, non-HER2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, bemarituzumab plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus chemotherapy.
04/
Jacobio Completes First Patient Dosing in United States for Pan-KRAS Inhibitor
Recently, Qiming Venture Partners portfolio company Jacobio (01167.HK) announced that its self-developed pan-KRAS inhibitor JAB-23E73 has completed first patient dosing in a phase 1/2a clinical trial in the United States. Dose-escalation studies in China are also progressing as planned.
JAB-23E73 is highly selective for KRAS, simultaneously inhibiting both active and inactive states of KRAS without significant inhibition of HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 demonstrated favorable pharmacokinetic properties and significant anti-tumor activity in preclinical studies.
05/
Jacobio BET Inhibitor JAB-8263 Autoimmune Indication Clinical Trial Application Accepted
Recently, Qiming Venture Partners portfolio company Jacobio (01167.HK) announced that it has submitted a phase 1/2 clinical trial application for BET inhibitor JAB-8263 in autoimmune diseases to the Center for Drug Evaluation, NMPA (CDE), which has been accepted.
"Autoimmune diseases affect 5-9% of the global population, and most current treatments are antibody injections with only a few oral drugs approved," said Dr. Yinxiang Wang, Chairman and CEO of Jacobio. "Through internal translational medicine research, we hope to extend the clinical value of BET inhibitors from oncology to autoimmune diseases, benefiting more patients."
06/
Belief BioMed Announces Latest Research Results for Xinjiuning® (Bepadocogene Autotemcel Injection) in Treatment of Hemophilia B
Recently, Qiming Venture Partners portfolio company Belief BioMed formally presented long-term follow-up data from an investigator-initiated clinical trial (IIT, NCT04135300) of its gene therapy drug Xinjiuning® (BBM-H901 injection, generic name: bepadocogene autotemcel injection) in adult patients with hemophilia B as an oral presentation at the 33rd International Society on Thrombosis and Haemostasis (ISTH) Congress.
The study showed that BBM-H901 injection was well tolerated, with vector-derived FIX activity levels remaining stably expressed over the long term, significantly reducing bleeding events and greatly decreasing hemophilia B patients' need for exogenous FIX product replacement therapy (prothrombin complex concentrate, coagulation factor IX).
07/
Sanegene Bio Completes First Subject Dosing in China for CFB-Targeting siRNA Drug for Complement-Related Diseases
Qiming Venture Partners portfolio company Sanegene Bio announced that its self-developed small nucleic acid (siRNA) drug SGB-3383 injection, targeting CFB, has successfully completed first subject dosing in its China phase 1 clinical study at Peking University Third Hospital. SGB-3383 is a siRNA drug targeting Complement Factor B (CFB) for the treatment of complement-mediated kidney-related diseases.
This clinical study is a randomized, double-blind, placebo-controlled, single-ascending-dose phase 1 study, primarily designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGB-3383 in healthy subjects. Preclinical data showed that SGB-3383 can significantly and persistently reduce CFB levels in the liver and blood, with good safety and tolerability.
08/
Berry Genomics Supports Chinese Academy of Agricultural Sciences Zhengzhou Fruit Research Institute Publication in Internationally Renowned Journal
Recently, the Watermelon and Melon Germplasm Resources Team at the Chinese Academy of Agricultural Sciences Zhengzhou Fruit Research Institute published a research paper in the internationally renowned journal Molecular Horticulture. Qiming Venture Partners portfolio company Berry Genomics (000710.SZ) contributed to parts of the sequencing, genome assembly, and resequencing analysis for the article.
The study employed multi-omics techniques to decode the dual genetic loci of a "double switch" controlling four distinct flesh color phenotypes in watermelon, offering new insights into plant carotenoid biosynthesis and color formation mechanisms.
Company Development
Dr. Weichang Zhou Joins MediLink Therapeutics as Chief Technology Officer
Recently, Qiming Venture Partners portfolio company MediLink Therapeutics announced the formal appointment of Dr. Weichang Zhou as Chief Technology Officer (CTO). Dr. Zhou's extensive industry experience in biopharmaceuticals will help strengthen MediLink Therapeutics' global development of its innovative pipeline.
Dr. Zhou brings over 30 years of distinguished industry experience and is widely recognized for his leadership and significant contributions to biologics development and manufacturing. He previously served as Executive Director, Chief Technology Officer, and President of Global Biologics Development and Operations at WuXi Biologics. Prior to joining WuXi Biologics in 2012, Dr. Zhou held senior CMC leadership positions at Genzyme Corporation (now part of Sanofi), PDL BioPharma Inc., and Merck & Co. Inc.
Dr. Zhou commented: "I am delighted to join MediLink Therapeutics. As a pioneering biotechnology company with exceptional innovative vitality and high-growth potential, MediLink Therapeutics' forward-looking战略布局 in the antibody-drug conjugate field is truly exciting. I look forward to working alongside the MediLink team to accelerate the development of our innovative drug pipeline, drive commercialization of core products, and bring high-quality antibody-drug conjugates to patients worldwide as soon as possible."
Product Launches
01/
UBTECH Unveils Next-Generation Cruzr Commercial Service Robot
Recently, Qiming Venture Partners portfolio company UBTECH (09880.HK) officially launched its next-generation Cruzr commercial service robot, ushering in an upgraded revolution in service intelligence.
The all-new Cruzr is more than a tool — it is a "service organism" with perception, decision-making, and evolutionary capabilities. Building on the classic humanoid design of its two predecessors, it features 15 degrees of freedom and omnidirectional wheel chassis for human-like movement, now enhanced with a large AI model that gives it understanding and adaptability beyond conventional robots. It will help global customers build "warm yet hyper-efficient service" through intelligent reception, professional guided tours, precise wayfinding, and multimodal interaction.
02/
Gan & Lee Pharmaceuticals' Insulin Aspart Injection Approved in Argentina
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its insulin aspart injection, developed in partnership with a local Argentine pharmaceutical company, has received registration approval from Argentina's National Administration of Drugs, Foods and Medical Devices (ANMAT). This approval marks Gan & Lee's second core product to enter the Argentine market following insulin glargine, further enriching the company's local product portfolio.
Through local filling partnerships, Gan & Lee Pharmaceuticals will effectively shorten supply cycles and further strengthen supply security in the Argentine market. This initiative delivers not only on the promise of availability, but also on the commitment to stability — aiming to build a sustainable insulin supply system that ensures patients have continuous, reliable access to treatment.
03/
Northern MedTech's TruePhysio X™ Wireless Pressure Microcatheter Approved by National Medical Products Administration
Recently, Qiming Venture Partners portfolio company Northern MedTech announced that its next-generation TruePhysio X™ wireless pressure microcatheter has received Class III medical device registration approval from China's National Medical Products Administration. As the first domestic fully integrated coronary functional assessment solution, the product provides "navigation-grade" tools for precision diagnosis and treatment of coronary artery disease. It features both epicardial coronary vessel functional assessment indices (FFR/cRR) and achieves more stable, reliable coronary microcirculatory resistance index (iMR) measurements through innovative multi-sensor adaptive dual-point flow velocity fusion technology.
The product incorporates Northern MedTech's pioneering multisensor-iMR (m-iMR) technology. In animal studies and clinical trials, the company's m-iMR measurement demonstrated stability advantages: it required 33% fewer saline injections to achieve stable measurements compared to competing products, with higher measurement stability that saves procedural time. Physicians can operate it independently after just a few trials.
Technology & Innovation
01/
WeRide W5 Unmanned Logistics Vehicle Approved for Road Testing Across Huangpu District, Guangzhou
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) officially announced that it has received the first batch of unmanned equipment road testing licenses in Huangpu District, Guangzhou. Its autonomous logistics vehicle Robovan W5 (hereinafter referred to as the "W5 unmanned logistics vehicle") has commenced road testing across the entire district. The W5 also obtained license plate "穗S·F0001试," making it the first approved unmanned logistics vehicle on the road in Huangpu District. Currently, WeRide is the first and only "licensed enterprise" in the district.
This follows the company's acquisition of a road testing license in Nansha District, Guangzhou in April this year, marking the second district-wide license for the W5 in Guangzhou. The expanding operational footprint signals WeRide's accelerating progress toward large-scale commercialization of unmanned logistics vehicles.
02/
Lixue Xia of Infinigence AI Participates in Summer Davos Parallel Forum, Sharing Industry Insights
At the parallel forum "Encounter Tianjin, Embrace the Future" — a private enterprise salon held alongside the 16th Annual Meeting of the New Champions of the World Economic Forum (Summer Davos 2025) — Lixue Xia, co-founder and CEO of Infinigence AI, a Qiming Venture Partners portfolio company, was invited to share industry insights alongside prominent private entrepreneurs.
In his remarks, Xia said that in the field of artificial intelligence, computing power serves as the "power grid" of the AI industry — its foundational role is comparable to that of water, electricity, roads, and bridges. As one of China's most representative emerging technology companies in the AI computing infrastructure sector, Infinigence AI hopes to leverage its strengths to contribute to Tianjin's vision of becoming a pioneer city for "full-stack AI."
Xia noted that Infinigence AI will build on its technological advantages to continue deepening its work in computing empowerment, driving the deep integration and widespread application of "AI+" across thousands of industries and millions of households, and providing higher-quality computing infrastructure services for global AI development.
03/
Lixue Xia of Infinigence AI Attends the 2025 Yabuli China Entrepreneurs Forum 11th Innovation Annual Conference
Recently, the 2025 Yabuli China Entrepreneurs Forum 11th Innovation Annual Conference was held in Hangzhou, Zhejiang Province. Lixue Xia, co-founder and CEO of Infinigence AI, a Qiming Venture Partners portfolio company, attended and delivered a keynote speech titled "Development of AI Software and Hardware Technologies and Infinigence AI's Industrial Practice."
Infinigence AI is one of the most representative AI infrastructure companies. Xia shared the company's practical industrial experience: in the cloud, Infinigence AI uses software-hardware co-design to build a "bridge" between chips and models, fully integrating and mixing different chips and models to facilitate efficient flow of system resources and data, helping achieve nationwide computing system connectivity, and enabling computing power and AI to flow into thousands of industries and millions of households in a standardized way, just like water and electricity. On the edge, software is applied to terminals to achieve 2-5x performance improvements. Through self-developed inference IP, AI runs quickly and economically on every computing unit, accelerating AI empowerment of various terminal devices. Infinigence AI remains committed to working with upstream and downstream partners to jointly build a "cloud-edge integrated" industrial ecosystem, collaboratively driving the localization of AI computing power and the inclusive deployment of AGI.
04/
CANbridge Pharmaceuticals Announces First Prescription for Gerining®, a Class 1 New Drug for Type I and Type III Gaucher Disease
Recently, CANbridge Pharmaceuticals (01228.HK), a Qiming Venture Partners portfolio company, announced that Gerining®, approved for market on May 13 for long-term enzyme replacement therapy in patients aged 12 and above with Type I and Type III Gaucher disease, had its first prescription filled at Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. This marks the official clinical application of China's first domestically self-developed enzyme replacement drug.
Clinical data shows that Gerining® significantly improves core Gaucher disease indicators: after nine months of treatment, spleen volume decreased by 35.32% and hemoglobin increased by 2.17 g/dL.
05/
Benewake Showcases at CEIVD 2025
At the 2025 China International Laboratory Medicine and In Vitro Diagnostics Exhibition (CEIVD 2025), Benewake, a Qiming Venture Partners portfolio company, highlighted its LabGenius G series pipetting robots and their cutting-edge application scenarios. The LabGenius G3 pipetting robot deeply integrates robotics technology, automation control, and AI algorithms, delivering core value to users in life sciences and clinical diagnostics through high-precision pipetting technology and multi-scenario application adaptability.
Going forward, Benewake will continue to deepen R&D in frontier technologies, using intelligent automation solutions to break down traditional application barriers, making automation technology accessible, unlocking scientific innovation potential, driving laboratories toward intelligent and efficient development, and injecting strong momentum into transformation in the life sciences field.
06/
Professor Li Gengyuan's Team at Hong Kong's Queen Elizabeth Hospital Performs Surgery Using TingSheng Technologies' Intracardiac Echocardiography Diagnostic System
Recently, in the cardiac interventional operating room at Hong Kong's Queen Elizabeth Hospital, Professor Li Gengyuan's team completed two special patent foramen ovale (PFO) closure surgeries. The procedures used real-time intracardiac imaging provided by the intracardiac echocardiography diagnostic system independently developed by TingSheng Technologies, a Qiming Venture Partners portfolio company. This application reduced trauma to patients and provided a new example of China's cardiovascular and cerebrovascular disease treatment technology advancing to the international frontier.
The system provided Professor Li Gengyuan's team with real-time, high-resolution intracardiac structural imaging, helping doctors precisely locate the PFO position and guide guidewires and catheters to safely pass through the unclosed foramen ovale, greatly improving surgical precision and safety.
07/
SceneRay Participates in 2025 Brain-Computer Interface Future Industry Forum and "Zhangjiang Sword" Sci-Tech Salon Phase IV BCI Event
Recently, as a leading Chinese medical application enterprise for brain-computer interface DBS technology, SceneRay, a Qiming Venture Partners portfolio company, was invited to attend the 2025 Brain-Computer Interface Future Industry Forum and the fourth phase of the "Zhangjiang Sword" Sci-Tech Salon focused on brain-computer interfaces.
SceneRay Chairman Ning Yihua introduced the advantageous application of invasive brain-computer interfaces in dual-target DBS for drug addiction treatment, combining it with the company's products. In his keynote speech "Disruptive Innovation in Brain-Computer Interface Dual-Target DBS for Drug Addiction Treatment," Ning used opioid addiction as an example. He emphasized that with nearly 300 million opioid addicts globally, traditional withdrawal methods (drug substitution plus psychological therapy) have high relapse rates. In response, SceneRay's technical team developed a brain-computer interface dual-target DBS stimulation chip for addiction disorders, with efficacy positively validated in subsequent clinical trials.
08/
Sinovision 128-Slice CT Stable Operation Exceeds 20 Months, Winning High Recognition from End Users
Sinovision, a Qiming Venture Partners portfolio company, previously won a bid for a World Bank-assisted medical project in Uzbekistan, delivering 128-slice CT equipment to 13 branches of its National Emergency Medical Center. As of May 2025, this equipment has been running continuously and stably for over 20 months, earning high recognition from end users.
The Karakalpakstan region in western Uzbekistan's desert zone is vast and sparsely populated, with extremely scarce medical resources. Local residents needing diagnosis of complex diseases often had to travel over 1,000 kilometers to the capital, Tashkent, for medical care. The installation of Sinovision's 128-slice CT equipment in Karakalpakstan has significantly alleviated this difficulty, providing great convenience for patients and making early disease diagnosis a reality.
Corporate Honors
Shengshu Technology Selected for 2025 Technology Pioneers List
The World Economic Forum recently announced its 2025 Technology Pioneers list. Qiming Venture Partners portfolio company Shengshu Technology was selected for its work building generative AI infrastructure and developing native multimodal large models for images, 3D, and video. The newly selected Technology Pioneers reflect broad shifts in the innovation ecosystem, with many companies harnessing AI to achieve scale and specialization with fewer resources.
Launched in 2000, the Technology Pioneers community marks its 25th anniversary in 2025. This leading platform brings together world-class startups at various stages of development — from early-stage Technology Pioneers to growth-stage Global Innovators and unicorns valued at over $1 billion. Companies selected for this year's Technology Pioneers list will contribute cutting-edge insights to the World Economic Forum's initiatives during a two-year engagement period.
Previous Coverage
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 23, 2025
Qiming Venture Partners was established in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its founding, Qiming Venture Partners has focused on investing in outstanding early and growth-stage companies in the Technology and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.